01/21/2026
IntraBio today announced positive pivotal Phase III trial results of levacetylleucine for the treatment of Ataxia-Telangiectasia, with statistically significant and clinically meaningful improvements across primary and key secondary endpoints. These data support planned regulatory submissions in the United States, Europe, and additional jurisdictions.
IntraBio Inc. today announced positive topline results from its pivotal Phase III IB1001-303 clinical trial, “Effects of N-Acetyl-L-Leucine on Ataxia-Telangi...